| Literature DB >> 34887318 |
Joanne McPeake1,2, Martin Shaw3,2, Pamela MacTavish3, Kevin G Blyth3,4, Helen Devine3, Gillian Fleming5, Justine Griffin3, Lisa Gemmell3, Pauline Grose3, Mark Henderson3, Philip Henderson3,2, Lucy Hogg5, Kirstin King3, Iain McInnes6, Peter O'Brien7, Kathryn Puxty3,2, Callum Rainey7, Varun Sharma3, Malcolm Sim3,2, Laura Strachan3, Stefan Siebert8, Tara Quasim3,2.
Abstract
BACKGROUND: There are limited data describing the long-term outcomes of severe COVID-19. We aimed to evaluate the long-term psychosocial and physical consequences of severe COVID-19 for patients.Entities:
Keywords: ARDS; COVID-19
Mesh:
Year: 2021 PMID: 34887318 PMCID: PMC8663070 DOI: 10.1136/bmjresp-2021-001080
Source DB: PubMed Journal: BMJ Open Respir Res ISSN: 2052-4439
Figure 1Patient flow through the study (invitation through to participation). InS:PIRE, Intensive Care Syndrome: Promoting Independence and Return to Employment; MDT, multidisciplinary team.
Patient baseline demographics (COVID-19 cohort)
| Characteristic | n=93 |
| Gender, male (%) | 61 (65.6) |
| Age, median years (IQR) | 59 (54–67) |
| Obesity (%) | 30 (32.3) |
| Black and minority ethnic (%) | 4 (4.3) |
| Smoking (%) | 7 (7.5) |
| Comorbidities | |
|
| 36 (38.7) |
|
| 11 (11.8) |
|
| 28 (30.1) |
|
| 23 (24.7) |
|
| 1 (1.1) |
|
| 12 (12.9) |
|
| 12 (12.9) |
|
| 47 (51.1) |
| Hospital length of stay, median, days (IQR) | 22 (12–55.7) |
| Critical care length of stay, median, days (IQR) | 11.1 (5–25.3) |
| Acute Physiology and Chronic Health Evaluation II Score, median (IQR) | 15 (10–20) |
| Invasive ventilation (%) | 63 (67.7) |
| Continuous positive airway pressure ventilation (never received invasive ventilation) (%) | 16 (17.2) |
| Continuous positive airway pressure ventilation (also received invasive ventilation) (%) | 11 (11.8) |
| Renal replacement therapy (%) | 18 (19.4) |
| Advanced cardiovascular support (%) | 35 (37.6) |
| Proned (%) | 36 (38.7) |
| Socioeconomic status: (SIMD category) | |
|
| 30 (32.3) |
|
| 19 (20.4) |
|
| 20 (21.5) |
|
| 8 (8.6) |
|
| 16 (17.2) |
| Employment status before admission | |
|
| 67 (72) |
|
| 6 (6.5) |
|
| 17 (18.3) |
|
| 3 (3.2) |
SIMD, Scottish Index of Multiple Deprivation.
Figure 2Distribution of hospital (A) and critical care (B) length of stay and APACHE II scores (C) in those returning to, and not returning to employment. APACHE II, Acute Physiology and Chronic Health Evaluation II.
Figure 3Breakdown in return to baseline employment status across the SIMD quintiles. SIMD, Scottish Index of Multiple Deprivation.
Breakdown of patient EQ-5D-5L domains and anatomical sites of pain described via the BPI (COVID-19 cohort)
| Outcome characteristic | n=93 |
| EQ-5D-5L | |
| EQ-5D-5L: mobility | |
|
| 44 (47.3) |
|
| 12 (12.9) |
|
| 22 (23.7) |
|
| 15 (16.1) |
|
| 0 (0) |
| EQ-5D-5L: self-care | |
|
| 66 (71) |
|
| 14 (15) |
|
| 9 (9.7) |
|
| 4 (4.3) |
|
| 0 (0) |
| EQ-5D-5L: usual activities | |
|
| 25 (26.8) |
|
| 24 (25.8) |
|
| 29 (31.2) |
|
| 13 (14) |
|
| 2 (2.2) |
| EQ-5D-5L: pain/discomfort | |
|
| 27 (29.1) |
|
| 19 (20.4) |
|
| 24 (25.8) |
|
| 20 (21.5) |
|
| 3 (3.2) |
| EQ-5D-5L: anxiety/depression | |
|
| 33 (35.5) |
|
| 22 (23.7) |
|
| 19 (20.4) |
|
| 15 (16.1) |
|
| 4 (4.3) |
| BPI* | |
| Pain location from BPI | |
|
| 8 |
|
| 18 |
|
| 20 |
|
| 26 |
|
| 38 |
*Sixty-five patients described pain via the BPI. Patients could describe more than one site of pain.
BPI, Brief Pain Inventory.
COVID-19 and non-COVID-19 cohorts, unmatched and matched datasets
| Characteristic/outcome | Pre-matching | Post-matching | ||||
| Non-COVID-19 | COVID-19 | P value | Non-COVID-19 | COVID-19 | P value | |
| No of patients | 206 | 93 | 91 | 91 | ||
| Age, median (IQR), years | 58.2 (50–65.7) | 59 (54–67) | 0.11 | 59.3 (52.5–66.7) | 60 (54–67) | 0.74 |
| Gender, male (%) | 112 (54.6) | 61 (65.6) | 0.08 | 56 (61.5) | 61 (67) | 0.44 |
| Follow-up time, days, median, (IQR) | 144 (96–181) | 113 (84–156) | 0.05 | 118 (86–166) | 142 (94–180) | 0.21 |
| Documented obesity on admission, no (%) | 50 (24.4) | 30 (32.3) | 0.16 | 24 (26.4) | 29 (31.9) | 0.41 |
| Prescence of 2 of multimorbidity (two or more comorbidities) (%) | 64 (31.2) | 47 (51.1) | <0.01 | 32 (35.2) | 45 (50) | 0.12 |
| Mental Health problems pre-ICU, no (%) | 68 (33.2) | 12 (12.9) | <0.01 | 15 (16.5) | 11 (12.1) | 0.40 |
| Critical Care Length of stay, median (IQR) days | 11.6 (5–25.3) | 11.1 (5–25.3) | 0.67 | 12.8 (7–23.7) | 11.1 (5–25.8) | 0.21 |
| APACHE II, median (IQR) | 20 (15–25) | 15 (10–20) | <0.01 | 17 (13–20.1) | 16 (12–19) | 0.08 |
| Socioeconomic status (SIMD category) | 0.13 | 0.71 | ||||
|
| 83 (40.5) | 29 (31.5) | 33 (36.2) | 28 (31.1) | ||
|
| 50 (24.4) | 19 (20.7) | 16 (17.6) | 19 (21.1) | ||
|
| 31 (15.1) | 20 (21.7) | 21 (23.1) | 20 (22.2) | ||
|
| 22 (10.7) | 8 (8.7) | 10 (11) | 7 (7.8) | ||
|
| 19 (9.3) | 16 (17.4) | 11 (12.1) | 16 (17.8) | ||
APACHE II, Acute Physiology and Chronic Health Evaluation II; SIMD, Scottish Index of Multiple Deprivation.
Figure 4Distribution of EQ-5D (HUS) (A) EQ-5D VAS (B) HADS anxiety (C) and HADS depression (D) across the COVID-19 and the non-COVID-19 cohorts. HADS, Hospital Anxiety and Depression Score; HUS, Health Utility Score; VAS, Visual Analogue Scale.